We develop innovative new anti-cancer therapies directed against a novel molecular target, whose mechanism of action involves multi-pathway. COARE Biotechnology is preclinical stage company, developing anti-cancer drugs that eliminate cancer stem cells, and also designs biomarkers for the detection of oncological protiens.
COARE Biotechnology, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/coare-biotechnology” connections=”true” suffix=””]
COAREs technology platform utilizes its proprietary siRNA mediated delivery platform and company is also developing panels of monoclonal antibodies against key stem cell signaling molecules expressed on tumor initiating cells.
COARE Biotechnology key partners includes Oklahoma SBIR Collaborative Resources (OSCR) and Oklahoma Center for the Advancement of Science and Technology (OCAST).
In Aug 2013, COARE Biotechnology was awarded with a $220,099 grant by the NIH to develop a new treatment for Pancreatic ductal adenocarcinoma (PDAC).